Abiraterone Acetate

證據等級: L5

預測適應症: 0 個

ABIRATERONE ACETATE: Drug Repurposing Evaluation — Awaiting Prediction Data

One-Sentence Summary

Abiraterone Acetate is a CYP17A1 inhibitor originally developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The TxGNN model has not yet generated any predicted new indications for this drug, and multiple critical data gaps remain unresolved — including mechanism of action details and safety labelling information. This report serves as a baseline assessment pending completion of data collection.

Quick Overview

Item	Content
Original Indication	Prostate cancer (known from drug class; no TFDA-approved indication on file)
Predicted New Indication	— (No TxGNN prediction available)
TxGNN Prediction Score	—
Evidence Level	L5 (No evidence; model prediction not yet available)
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack (flagged as Data Gap DG002). Based on publicly known information, Abiraterone Acetate is a prodrug of abiraterone, which acts as a selective, irreversible inhibitor of CYP17A1 (17α-hydroxylase/C17,20-lyase). This enzyme is critical in the androgen biosynthesis pathway. By blocking CYP17A1, abiraterone suppresses androgen production in the testes, adrenal glands, and prostate tumour tissue, making it effective in castration-resistant prostate cancer where residual androgen signalling drives tumour growth.

However, since no TxGNN-predicted indications have been generated, it is not possible to evaluate the mechanistic plausibility of any drug repurposing hypothesis at this time. The CYP17A1 inhibition mechanism could theoretically be relevant to other androgen-dependent conditions or hormone-sensitive malignancies, but this remains speculative without a specific prediction to evaluate.

The absence of prediction data may be attributable to incomplete knowledge graph coverage or pending model execution. This assessment should be revisited once TxGNN predictions become available.

Clinical Trial Evidence

Currently no predicted indication has been generated by TxGNN, therefore no indication-specific clinical trial search was performed.

Literature Evidence

Currently no predicted indication has been generated by TxGNN, therefore no indication-specific literature search was performed.

Taiwan Market Information

Abiraterone Acetate currently holds no TFDA marketing authorizations in Taiwan (市場狀態: 未上市). No license records are available.

Note: Abiraterone Acetate is marketed internationally under the brand name Zytiga® (Janssen/Johnson & Johnson) and has received approval from the US FDA (2011), EMA, and many other regulatory authorities for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

Cytotoxicity

Abiraterone Acetate is an antineoplastic agent used in prostate cancer treatment. Although it is not a conventional cytotoxic chemotherapy agent (it is a hormonal/targeted therapy), it falls within the antineoplastic category.

Item	Content
Cytotoxicity Classification	Targeted therapy (CYP17A1 inhibitor — hormonal/endocrine mechanism)
Myelosuppression Risk	Low (not a conventional cytotoxic; however, anaemia is a known adverse effect)
Emetogenicity Classification	Low
Monitoring Items	Liver function tests (ALT/AST — hepatotoxicity risk), blood pressure, serum potassium, cardiac function, CBC
Handling Protection	Standard precautions; not classified as a conventional cytotoxic requiring closed-system transfer. However, contraindicated in pregnancy — women who are or may become pregnant should avoid handling crushed or broken tablets.

Safety Considerations

All safety data fields in the Evidence Pack are currently flagged as data gaps (DG001 — Blocking severity). No TFDA package insert data, warnings, contraindications, or drug-drug interaction records were retrieved.

⚠️ Blocking Data Gap: TFDA package insert warnings and contraindications have not been obtained. This constitutes a blocking gap for Stage 1 safety screening. Please refer to the original manufacturer's package insert or international labelling (e.g., US FDA Zytiga® prescribing information) for comprehensive safety information.

Known safety concerns from international labelling (for reference only):

Mineralocorticoid excess: Hypertension, hypokalaemia, and fluid retention due to CYP17A1 blockade; must be co-administered with prednisone/prednisolone
Hepatotoxicity: Elevated transaminases; liver function monitoring required
Cardiac disorders: Cardiac failure, myocardial infarction, QT prolongation
Adrenocortical insufficiency: Risk if prednisone is interrupted

Data Gaps Summary

The following critical gaps must be resolved before this candidate can progress:

Gap ID	Category	Item	Severity	Remediation
DG001	Drug Level	TFDA Package Insert Warnings/Contraindications	Blocking	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Query DrugBank API
—	Prediction	TxGNN Predicted Indications	Blocking	Execute TxGNN model prediction pipeline
—	Drug Level	DrugBank ID	Medium	Confirm DrugBank entry (likely DB05812 or DB14685)

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN-predicted indications have been generated for Abiraterone Acetate, and multiple blocking data gaps remain unresolved (TFDA safety labelling, MOA data). Without a target indication to evaluate, it is not possible to assess repurposing feasibility. Additionally, the drug currently has no TFDA marketing authorization in Taiwan, which adds regulatory complexity to any repurposing pathway.

To proceed, the following is needed:

Run TxGNN prediction pipeline for Abiraterone Acetate to generate candidate indications
Resolve DG001 — Obtain and parse TFDA package insert (or confirm international labelling as reference)
Resolve DG002 — Query DrugBank API to populate MOA, DrugBank ID, and pharmacological classification
Confirm DrugBank ID — Likely DB05812 (abiraterone) or DB14685 (abiraterone acetate)
Re-run evidence collection (clinical trials + literature) once a predicted indication is available
Assess Taiwan regulatory pathway — Determine if an initial NDA/import license or off-label use pathway is viable
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.